REGENECORE is an innovative start-up company under the YOUNGY Group, advocating science and culture, paying attention to the growth of employees and enterprises, and maintaining human health.
Nanjing RegeneCore Biotech Co.,Ltd
Nanjing RegeneCore Biotech Co.,Ltd is established in the Biomedical Valley of National Nanjing Jiangbei New Area, with a research and office base of nearly 4000 square meters. It is one of the first research and development institutions in the field of nanobodies in China. The company's international scientific consulting expert team has rich experience in the research and development of cell therapy products and clinical applications, providing strong guarantees for the precise positioning and success rate of research and development products. The company has mature and leading nanobody screening technology, and conducts in-depth development in multiple application fields based on this technology.
High throughput nanobody screening technology platform, nanobody humanization technology platform, antibody immunogenicity detection technology platform, biomacromolecule analysis technology platform, antibody drug CMC process development technology platform
Learn more about RegeneCore news
All employees of REGENECORE carry out the Red Party Building Activity in the Ta-pieh Mountains
RegeneCore is the world's first IL4Rα-IL5 double antibody completed the first subject administration
REGENECORE RC1416 Injection Approved for Clinical Trial Application in the United States